NADAC acquisition cost data for ASPIRIN-DIPYRIDAM ER 25-200 MG. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 62559085060 | $0.7574 | 2022-10-19 | Rx |
| 62559085060 | $0.7574 | 2022-10-19 | Rx |
| 62559085060 | $0.7574 | 2022-10-19 | Rx |
| 00904705699 | $0.7628 | 2022-12-21 | Rx |
| 16714096401 | $0.7628 | 2022-12-21 | Rx |
| 42571027460 | $0.7628 | 2022-12-21 | Rx |
| 43598033960 | $0.7628 | 2022-12-21 | Rx |
| 49884000702 | $0.7628 | 2022-12-21 | Rx |
| 62175033035 | $0.7628 | 2022-12-21 | Rx |
| 65162059606 | $0.7628 | 2022-12-21 | Rx |
Generic: Aspirin/Dipyridamole | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $61.8M | 151,653 | 46,336 | $4.73 |
| 2020 | $37.8M | 103,583 | 39,563 | $3.75 |
| 2021 | $43.2M | 128,675 | 32,666 | $3.12 |
| 2022 | $41.8M | 129,098 | 27,025 | $2.97 |
| 2023 | $31.1M | 108,375 | 22,634 | $2.58 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.